---
title: The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic
  component of drug sensitivity
date: '2023-08-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37558831/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230810180951&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Aberrant DNA methylation accompanies genetic alterations during oncogenesis
  and tumour homeostasis and contributes to the transcriptional deregulation of key
  signalling pathways in cancer. Despite increasing efforts in DNA methylation profiling
  of cancer patients, there is still a lack of epigenetic biomarkers to predict treatment
  efficacy. To address this, we analyse 721 cancer cell lines across 22 cancer types
  treated with 453 anti-cancer compounds. We systematically detect the ...
disable_comments: true
---
Aberrant DNA methylation accompanies genetic alterations during oncogenesis and tumour homeostasis and contributes to the transcriptional deregulation of key signalling pathways in cancer. Despite increasing efforts in DNA methylation profiling of cancer patients, there is still a lack of epigenetic biomarkers to predict treatment efficacy. To address this, we analyse 721 cancer cell lines across 22 cancer types treated with 453 anti-cancer compounds. We systematically detect the ...